{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:23:49Z","timestamp":1761895429096},"reference-count":282,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.endonu.2012.01.002","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T15:52:01Z","timestamp":1328716321000},"page":"174-196","source":"Crossref","is-referenced-by-count":18,"title":["Gu\u00edas de pr\u00e1ctica cl\u00ednica para la evaluaci\u00f3n y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales"],"prefix":"10.1016","volume":"59","author":[{"given":"Rebeca","family":"Reyes Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"J\u00f3dar Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Garc\u00eda Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Romero Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"G\u00f3mez S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Luque Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariela","family":"Varsavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsoles","family":"Guadalix Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidoro","family":"Cano Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Ballesteros Pomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Vidal Casariego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Rozas Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Cort\u00e9s Berdonces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Fern\u00e1ndez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Calleja Canelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Palma Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Mart\u00ednez D\u00edaz-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J.","family":"Jimenez Mole\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mu\u00f1oz Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endonu.2012.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1464-5491.2008.02608.x","article-title":"Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes","volume":"26","author":"Hamilton","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/07315724.2010.10719859","article-title":"Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in youngadult women: a disease complication often ignored or neglected","volume":"29","author":"Mass\u00e9","year":"2010","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jdiacomp.2009.10.002","article-title":"Bone mass and sex steroids in postmenarcheal adolescents and adult women with Type 1 diabetes mellitus","volume":"25","author":"Soto","year":"2011","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.endonu.2012.01.002_bib0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4158\/EP.7.5.346","article-title":"Bone mineral density at time of clinical diagnosis of adult- onset type 1 diabetes mellitus","volume":"7","author":"Lopez-Ibarra","year":"2001","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endonu.2012.01.002_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s001980070114","article-title":"Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study","volume":"11","author":"Campos Pastor","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/BF02509378","article-title":"Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin- dependent diabetes mellitus","volume":"58","author":"Mu\u00f1oz-Torres","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0045","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/(SICI)1096-9136(199712)14:12<1038::AID-DIA509>3.0.CO;2-1","article-title":"Microalbuminuria as an early indicator of osteopenia in male insulin-dependent diabetic patients","volume":"14","author":"Clausen","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0050","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2337\/diacare.22.5.827","article-title":"Impact of peripheral neuropathy on bone density in patients with type 1 diabetes","volume":"22","author":"Rix","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2012.01.002_bib0055","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s001250051071","article-title":"Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus","volume":"41","author":"Hampson","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.endonu.2012.01.002_bib0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2796.2003.01283.x","article-title":"Body composition and bone mineral density in long-standing type 1 diabetes","volume":"255","author":"Ingberg","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00592-005-0183-1","article-title":"Influence of diabetes on peripheral bone mineral density in men: A controlled study","volume":"42","author":"Bridges","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","article-title":"Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture","volume":"166","author":"Janghorbani","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0075","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.2337\/diacare.28.12.2850","article-title":"Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study inSweden","volume":"28","author":"Miao","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2012.01.002_bib0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00198-005-0013-x","article-title":"Diabetes mellitus and the risk of non-vertebral fractures: The Troms\u00f8 Study","volume":"17","author":"Ahmed","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-5491.2011.03286.x","article-title":"Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes","volume":"28","author":"Neumann","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0090","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1359\/jbmr.2003.18.4.784","article-title":"Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study","volume":"18","author":"Hanley","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0095","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.endonu.2012.01.002_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00223-010-9450-4","article-title":"Are antiresorptive drugs effective against fractures in patients with diabetes?","volume":"88","author":"Vestergaard","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdiacomp.2007.06.004","article-title":"Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes","volume":"23","author":"Anaforoglu","year":"2009","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.endonu.2012.01.002_bib0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF03324895","article-title":"Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study","volume":"21","author":"Sosa","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jocd.2008.09.003","article-title":"Bone mineral density in premenopausal Arab women with type 2 diabetes mellitus","volume":"12","author":"Gupta","year":"2009","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.endonu.2012.01.002_bib0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diabres.2010.09.013","article-title":"Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes","volume":"90","author":"Zhou","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endonu.2012.01.002_bib0125","first-page":"162","article-title":"Bone mineral density in patients with type 2 diabetes","volume":"63","author":"Sauque-Reyna","year":"2011","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.endonu.2012.01.002_bib0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF03347065","article-title":"Age-related bone mineral density, osteoporosis rate and risk of vertebral fracture in mainland Chinese women with type 2 diabetes mellitus","volume":"34","author":"Shan","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endonu.2012.01.002_bib0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0140","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1359\/jbmr.081207","article-title":"Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications","volume":"24","author":"Yamamoto","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0145","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.24.7.1198","article-title":"Diabetes and risk of fracture: The Blue Mountains Eye Study","volume":"24","author":"Ivers","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2012.01.002_bib0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jc.86.1.32","article-title":"Older women with diabetes have an increased risk of fracture: a prospective study","volume":"86","author":"Schwartz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0155","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.165.14.1612","article-title":"Nontraumatic fracture risk with diabetes mellitus and impaired fasting glu- cose in older white and black adults: The Health Aging, and Body Composition Study","volume":"165","author":"Strotmeyer","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0160","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00198-005-1909-1","article-title":"Bone mineral density and fracture risk in type-2 diabetes mellitus: The Rotterdam Study","volume":"16","author":"De Liefde","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","article-title":"Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus","volume":"28","author":"Kanazawa","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0170","doi-asserted-by":"crossref","unstructured":"Kim JH, Jung MH, Lee JM, Son HS, Cha BY, Chang SA. Diabetic peripheral neuropathy is highly associated with non-traumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2011 Epub Sep 12.","DOI":"10.1111\/j.1365-2265.2011.04222.x"},{"key":"10.1016\/j.endonu.2012.01.002_bib0175","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2012.01.002_bib0180","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bone.2009.06.006","article-title":"Vertebral fractures in males with type 2 diabetes treated with rosiglitazone","volume":"45","author":"Mancini","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.endonu.2012.01.002_bib0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2009-1385","article-title":"Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus","volume":"95","author":"Habib","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0190","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2012.01.002_bib0195","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.27.7.1547","article-title":"Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial","volume":"27","author":"Keegan","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2012.01.002_bib0200","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/BF02877778","article-title":"Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis","volume":"24","author":"Dagdelen","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2008-1760","article-title":"Presentation of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop","volume":"94","author":"Silverberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0210","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0215","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0220","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1999.14.10.1700","article-title":"Primary hyperparathyroidism and the risk of fracture: a population-based study","volume":"14","author":"Khosla","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0225","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","article-title":"Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism","volume":"321","author":"Vestergaard","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","article-title":"Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0235","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bmj.327.7414.530","article-title":"Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism","volume":"327","author":"Vestergaard","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0240","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/jc.2007-0219","article-title":"Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial","volume":"92","author":"Ambrogini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0245","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00268-011-1062-2","article-title":"Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden","volume":"35","author":"Siilin","year":"2011","journal-title":"World J Surg"},{"issue":"Suppl 2","key":"10.1016\/j.endonu.2012.01.002_bib0250","first-page":"N103","article-title":"Fracture risk in primary hyperparathyroidism","volume":"17","author":"Khosla","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0255","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/jc.2008-1757","article-title":"Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited","volume":"94","author":"Khan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0260","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0265","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2008-1761","article-title":"Surgery for asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop","volume":"94","author":"Udelsman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/jc.2008-1762","article-title":"Medical management of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop","volume":"94","author":"Khan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0275","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/105072503322238854","article-title":"Hyperthyroidism, bone mineral, and fracture risk a meta-analysis","volume":"13","author":"Vestergaard","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.endonu.2012.01.002_bib0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/105072502760043503","article-title":"Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients","volume":"12","author":"Vestergaard","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.endonu.2012.01.002_bib0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-5122(00)00179-1","article-title":"Early postmenopausal bone loss in hyperthyroidism","volume":"39","author":"Ben-Shlomo","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.endonu.2012.01.002_bib0300","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1365-2265.1997.2261041.x","article-title":"Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause","volume":"47","author":"Jodar","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 6","key":"10.1016\/j.endonu.2012.01.002_bib0305","first-page":"S1","article-title":"A comparative study of bone mineral density between premenopausal women with hyperthyroidism and healthy premenopausal women","volume":"93","author":"Boonya-Ussadorn","year":"2010","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.endonu.2012.01.002_bib0310","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0315","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00223-005-0068-x","article-title":"Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk","volume":"77","author":"Vestergaard","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0320","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","article-title":"Risk for fracture in women with low serum levels of thyroid-stimulating hormone","volume":"134","author":"Bauer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0325","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1210\/jc.78.4.955","article-title":"Markers of bone turnover in hyperthyroidism and the effects of treatment","volume":"78","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0889-8529(18)30338-4","article-title":"Effects of thyroid hormones on bone and mineral metabolism","volume":"19","author":"Mosekilde","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.endonu.2012.01.002_bib0335","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2265.2004.02110.x","article-title":"Bone mineral density in hyperthyroidism","volume":"61","author":"Karga","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0340","first-page":"947","article-title":"Evaluation of bone mineral density in thyrotoxicosis","volume":"47","author":"Udayakumar","year":"2006","journal-title":"Singapore Med J"},{"key":"10.1016\/j.endonu.2012.01.002_bib0345","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5122(00)00114-6","article-title":"Variable bone mass recovery in hyperthyroid bone disease after radioiodine therapy in postmenopausal patients","volume":"35","author":"Obermayer-Pietsch","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.endonu.2012.01.002_bib0350","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1210\/jc.82.6.1989","article-title":"Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism","volume":"82","author":"Jodar","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-120-1-199401010-00002","article-title":"Thyrotoxic bone disease in women: a potentially reversible disorder","volume":"120","author":"Diamond","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1507\/endocrj.50.657","article-title":"Bone and calcium metabolism in subclinical autoinmune hyperthyroidism and hypothyroidism","volume":"50","author":"Kisakol","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.endonu.2012.01.002_bib0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2265.1993.tb02403.x","article-title":"Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?","volume":"39","author":"F\u00f6ldes","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0370","first-page":"62","article-title":"Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women","volume":"6","author":"Belaya","year":"2007","journal-title":"Hormones Athens"},{"key":"10.1016\/j.endonu.2012.01.002_bib0375","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1001\/archinternmed.2010.424","article-title":"Subclinical thyroid dysfunction and incident hip fracture in older adults","volume":"170","author":"Lee","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0380","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.maturitas.2004.02.017","article-title":"Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism","volume":"48","author":"Tauchmanov\u00e0","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.endonu.2012.01.002_bib0385","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1210\/jc.2010-2693","article-title":"The thyroid epidemiology, autid, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism","volume":"96","author":"Vadiveloo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0390","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.82.9.2931","article-title":"Low thyrotropin levels are not associated with bone loss in older women: a prospective study","volume":"82","author":"Bauer","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0395","first-page":"27","article-title":"Bone metabolism in premenopausal women with nontoxic goiter and reduced serum thyrotropin levels","volume":"6","author":"Faber","year":"1994","journal-title":"Thyroidology"},{"key":"10.1016\/j.endonu.2012.01.002_bib0400","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1081\/ERC-120026945","article-title":"Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves\u2019 disease with subclinical hyperthyroidism","volume":"290","author":"Ugur-Altun","year":"2003","journal-title":"Endocr Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0405","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2265.1998.00427.x","article-title":"Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism. Effect of bone loss in postmenopausal women","volume":"48","author":"Faber","year":"1998","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0410","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1994.tb02571.x","article-title":"Bone metabolism during anti thyroid drug treatment of endogenous subclinical hyperthyroidism","volume":"41","author":"Muddle","year":"1994","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00198-005-1892-6","article-title":"Self-reported diseases and the risk of non-vertebral fractures: the Troms\u00f8 study","volume":"17","author":"Ahmed","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2265.1998.3871200.x","article-title":"Effect of replacement doses of thyroxine on bone mineral density","volume":"48","author":"Hanna","year":"1998","journal-title":"Clin Endocrinol (oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0425","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1530\/eje.0.1510689","article-title":"Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism","volume":"151","author":"Salerno","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0430","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1210\/jc.81.12.4278","article-title":"Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis","volume":"81","author":"Uzzan","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0435","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1136\/bmj.d2238","article-title":"Levothyroxine dose and risk of fractures in older adults: nested case-control study","volume":"342","author":"Turner","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0440","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1507\/endocrj.K06-201","article-title":"Subclinical hypothyroidism is related to lower Heel QUS in postmenopausal women","volume":"54","author":"Nagata","year":"2007","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.endonu.2012.01.002_bib0445","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.arcmed.2005.09.009","article-title":"Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women","volume":"37","author":"Lee","year":"2006","journal-title":"J Arch Med Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0450","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-003-1527-8","article-title":"Restoration of euthyroidism accelerates bone turnover in patients eith subclinical hypothyroidism: a randomized controlled trial","volume":"15","author":"Meier","year":"2004","journal-title":"Osteoporos int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0455","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1530\/eje.0.1300350","article-title":"Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis","volume":"130","author":"Faber","year":"1994","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.endonu.2012.01.002_bib0460","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/00016349609054714","article-title":"Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism","volume":"75","author":"Affinito","year":"1996","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.endonu.2012.01.002_bib0465","first-page":"442","article-title":"Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma","volume":"103","author":"Chen","year":"2004","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.endonu.2012.01.002_bib0470","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s001980050069","article-title":"Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass","volume":"8","author":"Jodar","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0475","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2265.1997.3221125.x","article-title":"Prospective study of bone loss in pre- and postmenopausal women on L-thyroxine therapy for non-toxic goiter","volume":"47","author":"De Rosa","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0480","first-page":"480","article-title":"Bone mineral density changes and bone turnover in thyroid carcinoma patienets treated with supraphysiologic doses of thyroxine","volume":"10","author":"Karner","year":"2005","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0485","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1185\/030079906X115612","article-title":"Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy","volume":"22","author":"Mazokopakis","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.endonu.2012.01.002_bib0490","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/eje.1.01933","article-title":"Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma","volume":"153","author":"Hejickmann","year":"2005","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.endonu.2012.01.002_bib0495","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/09513599809012835","article-title":"Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy","volume":"12","author":"Nuzzo","year":"1998","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0500","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000089489","article-title":"Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study","volume":"64","author":"Appetechia","year":"2005","journal-title":"Horm Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0505","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2796.2002.00977.x","article-title":"Treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size","volume":"251","author":"Baldini","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0510","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jad.2004.08.011","article-title":"Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders. A longitudinal study","volume":"83","author":"Bauer","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.endonu.2012.01.002_bib0515","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2265.1997.1280950.x","article-title":"Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine","volume":"46","author":"Guo","year":"1997","journal-title":"Clin Endocrinol (oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.0269-4727.2003.00508.x","article-title":"Effects of levothyroxina suppressive therapy on bone mineral density in premenopausal women","volume":"29","author":"Larijani","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib0525","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.1997.12.1.72","article-title":"Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine","volume":"12","author":"Marcocci","year":"1997","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0530","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/jc.83.7.2324","article-title":"Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine but is increased by cyclic intravenous pamidronate","volume":"83","author":"Rosen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 3","key":"10.1016\/j.endonu.2012.01.002_bib0535","first-page":"S71","article-title":"The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women","volume":"88","author":"Sajjinanont","year":"2005","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.endonu.2012.01.002_bib0540","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2009-1625","article-title":"Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patiens on long-term thyroxine therapy","volume":"95","author":"Flynn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0545","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1701-2163(16)32661-5","article-title":"Metabolic fuel and clinical implications for female reproduction","volume":"29","author":"Mircea","year":"2007","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.endonu.2012.01.002_bib0550","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1083-3188(00)00059-0","article-title":"Bone density issues in the adolescent gynecology patient","volume":"13","author":"Gordon","year":"2000","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0555","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2265.2010.03861.x","article-title":"How do you monitor the patient with Turner's syndrome in adulthood?","volume":"73","author":"Conway","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0560","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3109\/09513590.2010.486452","article-title":"Hypoestrogenism in young women and its influence on bone mass density","volume":"26","author":"Meczekalski","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0565","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0570","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0575","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0580","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.endonu.2012.01.002_bib0585","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.endonu.2012.01.002_bib0590","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss inbreast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0595","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitorinduced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0600","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0605","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0610","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1464-410X.2006.06584.x","article-title":"The clinical significance of bone mineral density and testosterone levels in Korean men with non-mosaic Klinefelter's syndrome","volume":"99","author":"Seo","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0615","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1297-319X(00)00235-9","article-title":"Gonadal dysgenesis and bone metabolism","volume":"68","author":"Breuil","year":"2001","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.endonu.2012.01.002_bib0620","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s001980170158","article-title":"Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution","volume":"12","author":"Van den Bergh","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0625","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.mcna.2011.03.001","article-title":"Late-onset hypogonadism","volume":"95","author":"Bassil","year":"2011","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.endonu.2012.01.002_bib0630","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00198-005-1879-3","article-title":"Alendronate for osteoporosis in men with androgen-repleted hypogonadism","volume":"16","author":"Shimon","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0635","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0640","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0645","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonist for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0650","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of Fracture after Androgen Deprivation for Prostate Cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0655","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0660","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1464-410X.2007.06853.x","article-title":"Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid","volume":"100","author":"Ryan","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0665","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zolendronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.endonu.2012.01.002_bib0670","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","article-title":"Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone","volume":"1","author":"Saad","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.endonu.2012.01.002_bib0675","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0680","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0685","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0690","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0695","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1210\/jc.84.6.1919","article-title":"Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0700","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1210\/jc.2003-030685","article-title":"Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0705","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1530\/acta.0.1290201","article-title":"Reduced bone mineral content in adult patients with growth hormone deficiency","volume":"129","author":"Ros\u00e9n","year":"1993","journal-title":"Acta Endocrinologica"},{"key":"10.1016\/j.endonu.2012.01.002_bib0710","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1210\/jc.82.5.1462","article-title":"Elderly Patients with Adult-Onset Growth Hormone Deficiency Are Not Osteopenic","volume":"82","author":"Toogood","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0715","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1530\/eje.0.1370240","article-title":"Increased fracture frequency in adult patients with hypopituitarism and GH deficiency","volume":"137","author":"Ros\u00e9n","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0720","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0300-0664.2001.01464.x","article-title":"Fracture risk is increased in patients with GH deficiency or untreated prolactinomas \u2013 a case-control study","volume":"56","author":"Vestergaard","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0725","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1359\/jbmr.2001.16.2.398","article-title":"The Influence of Growth Hormone Deficiency. Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral Density","volume":"16","author":"W\u00fcster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0730","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","article-title":"Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy","volume":"21","author":"Mazziotti","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0735","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2265.1995.tb02690.x","article-title":"Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency","volume":"42","author":"Holmes","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0740","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1210\/jc.83.1.107","article-title":"The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults","volume":"83","author":"Cuneo","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0745","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2265.1998.00439.x","article-title":"Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults","volume":"48","author":"Kann","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0750","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2265.1998.00465.x","article-title":"Long-term changes in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy","volume":"48","author":"Rahim","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0755","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1210\/jc.81.9.3352","article-title":"Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study","volume":"81","author":"Hansen","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0760","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/eje.1.02317","article-title":"Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency","volume":"156","author":"G\u00f6therstr\u00f6m","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0765","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1210\/jc.86.7.3079","article-title":"Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial","volume":"86","author":"Biermasz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0770","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2265.2004.02021.x","article-title":"Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study","volume":"60","author":"Biermasz","year":"2004","journal-title":"Clin Endocinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0775","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/jc.2010-1929","article-title":"Effect of Oral Phosphate and Alendronate on Bone Mineral Density when given as adjunctive therapy to growth hormone replacement in Adult Growth hormone deficiency","volume":"93","author":"White","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0780","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/jc.2003-030126","article-title":"Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled Dose-Ranging Study","volume":"88","author":"Shalet","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0785","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1210\/jc.2002-021541","article-title":"The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth","volume":"88","author":"Drake","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0790","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1210\/jc.2003-030204","article-title":"Growth Hormone (GH) Dose-Response in Young Adults with Childhood-Onset GH Deficiency: A Two-Year, Multicenter, Multiple-Dose Placebo-Controlled Study","volume":"88","author":"Underwood","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0795","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing's syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.50.1","article-title":"Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome","volume":"50","author":"Ohmori","year":"2003","journal-title":"Endocr J"},{"key":"10.1016\/j.endonu.2012.01.002_bib0805","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1210\/jc.2005-0582","article-title":"Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status","volume":"91","author":"Tauchmanov\u00e0","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0810","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-07-0137","article-title":"Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism","volume":"157","author":"Tauchmanov\u00e0","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0815","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02067","article-title":"Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study","volume":"154","author":"Kristo","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0820","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00198-007-0514-x","article-title":"Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome","volume":"19","author":"F\u00fcto","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0825","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2265.1998.00486.x","article-title":"Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease","volume":"48","author":"Di Somma","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0830","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/jc.84.7.2381","article-title":"Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism","volume":"84","author":"Torlontano","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0835","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.85.4.1440","article-title":"Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features","volume":"85","author":"Rossi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0840","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1210\/jc.86.2.604","article-title":"The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis","volume":"86","author":"Osella","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0845","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1365-2265.2003.01676.x","article-title":"Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?","volume":"58","author":"Hadjidakis","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0850","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1210\/jc.2009-0468","article-title":"Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study","volume":"94","author":"Chiodini","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0855","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1210\/jc.2003-031413","article-title":"Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status","volume":"89","author":"Chiodini","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0860","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1210\/jc.86.11.5337","article-title":"Bone loss rate in adrenal incidentalomas: a longitudinal study","volume":"86","author":"Chiodini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0865","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/jbmr.398","article-title":"Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study","volume":"26","author":"Morelli","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0870","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF03346473","article-title":"Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome","volume":"32","author":"Tauchmanova","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endonu.2012.01.002_bib0875","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s001980050251","article-title":"Bone mineral density in patients with treated Addison's disease","volume":"10","author":"Braatvedt","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib0880","article-title":"Bone Mineral Density Is Not Significantly Reduced in Adult Patients on Low-Dose Glucocorticoid Replacement Therapy","author":"Koetz","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0885","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/bmj.294.6575.798","article-title":"Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass","volume":"294","author":"Devegelaer","year":"1987","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2012.01.002_bib0890","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0169-6009(08)80158-4","article-title":"Bone density and turnover in Addison's disease: effect of glucocorticoid treatment","volume":"26","author":"Valero","year":"1994","journal-title":"Bone Miner"},{"key":"10.1016\/j.endonu.2012.01.002_bib0895","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2265.2003.01761.x","article-title":"Long-term follow-up of bone mineral density in Addison's disease","volume":"58","author":"Jodar","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0900","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-120-3-199402010-00005","article-title":"Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease","volume":"120","author":"Zelissen","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib0905","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12020-010-9359-8","article-title":"Co-morbidities, management and clinical outcome of auto-inmune Addison's disease","volume":"38","author":"Leelarathna","year":"2010","journal-title":"Endocrine"},{"key":"10.1016\/j.endonu.2012.01.002_bib0910","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone","volume":"160","author":"Lovas","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2007-1134","article-title":"Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial","volume":"93","author":"Gurnell","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0920","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1210\/jc.2003-031756","article-title":"Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and decrease in bone mass","volume":"89","author":"Coates","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0925","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ciresp.2010.04.008","article-title":"Bone mass loss after sleeve gastrectomy: a prospective comparative study with gastric bypass","volume":"88","author":"Nogu\u00e9s","year":"2010","journal-title":"Cir Esp"},{"key":"10.1016\/j.endonu.2012.01.002_bib0930","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/oby.2007.639","article-title":"Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs","volume":"15","author":"Dixon","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.endonu.2012.01.002_bib0935","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1590\/S0100-879X2006005000074","article-title":"Impact of marked weight loss induced by bariatric surgery on bone mineral density and remodeling","volume":"40","author":"Pereira","year":"2007","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0940","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/oby.2004.7","article-title":"Bone and gastric bypass surgery: effects of dietary calcium and vitamin D","volume":"12","author":"Goode","year":"2004","journal-title":"Obes Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib0945","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s11695-009-9843-5","article-title":"Evaluation of bone disease in morbidly obese women after gastric bypass and risk factors implicated in bone loss","volume":"19","author":"Vilarrasa","year":"2009","journal-title":"Obes Surg"},{"key":"10.1016\/j.endonu.2012.01.002_bib0950","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/BOR.0b013e328346f832","article-title":"Obesity, bariatric surgery, and bone","volume":"23","author":"Soleymani","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.endonu.2012.01.002_bib0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.14.S1.1","article-title":"The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient","volume":"14","author":"Mechanick","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endonu.2012.01.002_bib0960","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4158\/EP11105.RA","article-title":"Bariatric surgery and the role of the clinical endocrinologist: 2011 update","volume":"17","author":"Mechanick","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endonu.2012.01.002_bib0965","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1210\/jc.2009-2128","article-title":"Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society clinical practice guideline","volume":"95","author":"Heber","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib0970","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s11695-009-9850-6","article-title":"Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass","volume":"19","author":"Tondapu","year":"2009","journal-title":"Obes Surg"},{"key":"10.1016\/j.endonu.2012.01.002_bib0975","doi-asserted-by":"crossref","first-page":"634614","DOI":"10.1155\/2011\/634614","article-title":"Metabolic bone disease in the bariatric surgery patient","volume":"2011","author":"Williams","year":"2011","journal-title":"J Obes"},{"key":"10.1016\/j.endonu.2012.01.002_bib0980","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.soard.2008.08.004","article-title":"Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial","volume":"5","author":"Carlin","year":"2009","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.endonu.2012.01.002_bib0985","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005;128:1\u20139.","DOI":"10.1053\/j.gastro.2005.02.007"},{"key":"10.1016\/j.endonu.2012.01.002_bib0990","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.mog.0000208460.46395.9b","article-title":"Advances in celiac disease","volume":"22","author":"Jones","year":"2006","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib0995","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00198-008-0624-0","article-title":"Bone in celiac disease","volume":"19","author":"Bianchi","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib1000","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.2006.117382","article-title":"Gut, inflammation and osteoporosis: basic and clinical concepts","volume":"57","author":"Tilg","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.endonu.2012.01.002_bib1005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bpg.2005.01.002","article-title":"Bones in coeliac disease: diagnosis and treatment","volume":"19","author":"Corazza","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1010","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00042737-200510000-00009","article-title":"Should patients with coeliac disease have their bone mineral density measured?","volume":"17","author":"Lewis","year":"2005","journal-title":"Eur J Gastroenterol & Hepatol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1015","unstructured":"Lewis NR and Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and celiac disease. British Society of Gastroenterology. [consultado Jun 2007].Disponible en: http:\/\/www.bsg.org.uk"},{"key":"10.1016\/j.endonu.2012.01.002_bib1020","first-page":"112","article-title":"Osteoporosis in a North American adult population with celiac disease","volume":"96","author":"Meyer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1155\/2010\/285036","article-title":"Positive celiac disease serology and reduced bone mineral density in adult women","volume":"24","author":"Duerksen","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1030","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3748\/wjg.v17.i25.3035","article-title":"Risk of fracture in celiac disease: Gender, dietary compliance, or both?","volume":"17","author":"Pinto S\u00e1nchez","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1035","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s10620-007-9976-0","article-title":"Long-term fracture risk in patients with celiac disease: a population-based study in Olmsted County, Minnesota","volume":"53","author":"Jafri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.endonu.2012.01.002_bib1040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dld.2007.09.006","article-title":"Systematic review and meta-analysis of observational studies on the prevalence of fractures in celiac disease","volume":"40","author":"Olmos","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.endonu.2012.01.002_bib1045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2003.07.002","article-title":"Screening for asymptomatic celiac disease among patients referred for bone densitometry measurement","volume":"33","author":"Drummond","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.endonu.2012.01.002_bib1050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-001-1027-9","article-title":"Is it necessary to screen for celiac disease in postmenopausal osteoporotic women?","volume":"71","author":"Gonz\u00e1lez","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib1055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jbspin.2007.01.025","article-title":"Is screening for celiac disease in osteoporotic post-menopausal women necessary?","volume":"74","author":"Laadhar","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.endonu.2012.01.002_bib1060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jbspin.2008.06.016","article-title":"Screening for celiac disease in patients with osteoporosis","volume":"76","author":"Legroux-G\u00e9rot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.endonu.2012.01.002_bib1065","first-page":"506","article-title":"Osteoporosis and gastrointestinal disease","volume":"6","author":"Katz","year":"2010","journal-title":"Gastroenterol Hepatology"},{"key":"10.1016\/j.endonu.2012.01.002_bib1070","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1359\/JBMR.040319","article-title":"Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease","volume":"19","author":"Taranta","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib1075","first-page":"1480","article-title":"Hypocalciuria in overt and subclinical celiac disease","volume":"90","author":"Ciacci","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1080","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00251-005-0033-x","article-title":"The IL-1 gene family and bone involvement in celiac disease","volume":"57","author":"Moreno","year":"2005","journal-title":"Immunogen"},{"key":"10.1016\/j.endonu.2012.01.002_bib1085","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa0810925","article-title":"Osteoporosis Associated with Neutralizing Autoantibodies against Osteoprotegerin","volume":"361","author":"Riches","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ajcn\/67.3.477","article-title":"Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease","volume":"67","author":"Mora","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1572-0241.1999.867_r.x","article-title":"Bone density and bone metabolism are normal after long-term gluten-free diet in Young celiac patients","volume":"94","author":"Mora","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1100","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(99)04855-2","article-title":"Severe osteopenia in symptom-free adults with a childhood diagnosis of celiac disease","volume":"355","author":"Cellier","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2012.01.002_bib1105","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gut.2006.100511","article-title":"Long-term follow-up of 61 coeliac patient diagnosed in childhood: evolution toward latency is possible on a normal diet","volume":"56","author":"Matysiak-Budnik","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.endonu.2012.01.002_bib1110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S8756-3282(99)00171-4","article-title":"Bone recovery after a gluten-free diet: a 5-year follow-up study","volume":"25","author":"Kemppainen","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.endonu.2012.01.002_bib1115","first-page":"992","article-title":"Effects of dietary treatment on bone mineral density in adults with celiac disease: factors predicting response","volume":"92","author":"Ciacci","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jocd.2011.06.002","article-title":"Longitudinal evaluation of bone mineral density and body composition in patients with positive celiac serology","volume":"14","author":"Duerksen","year":"2011","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.endonu.2012.01.002_bib1125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/003655200750024146","article-title":"Three years\u2019 follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism","volume":"35","author":"Valdimarsson","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1130","first-page":"313","article-title":"Effect of treatment on bone mass, mineral metabolism and body composition in untreated celiac disease patients","volume":"92","author":"Mautalen","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00198-004-1641-2","article-title":"Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake","volume":"16","author":"Pazianas","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib1140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrendo.2009.272","article-title":"Treatment of postmenopausal osteoporosis in a patient with celiac disease","volume":"6","author":"Pinkerton","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.40.2.228","article-title":"Reduced bone density in patients with inflammatory bowel disease","volume":"40","author":"Bjarnason","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.endonu.2012.01.002_bib1150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1572-0241.1998.468_q.x","article-title":"Femoral neck osteopenia in patients with inflammatory bowel disease","volume":"93","author":"Pollak","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365520310007873","article-title":"Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study","volume":"39","author":"Jahnsen","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2796.2000.00582.x","article-title":"Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis","volume":"247","author":"Ardizzone","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aje\/kwf007","article-title":"Fracture risk in patients with celiac disease. Crohn's disease, and Ulcerative Colitis: a Nationwide Follow-up Study of 16,416 Patients in Denmark","volume":"156","author":"Vestergaard","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-133-10-200011210-00012","article-title":"The Incidence of Fracture among Patients with Inflammatory Bowel Disease. A Population-Based Cohort Study","volume":"133","author":"Bernstein","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1175","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/gast.2002.34779","article-title":"Long-Term Fracture Risk in Patients with Crohn's Disease: A Population-Based Study in Olmsted County, Minnesota","volume":"123","author":"Loftus","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.endonu.2012.01.002_bib1180","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1053\/j.gastro.2003.09.027","article-title":"Inflammatory Bowel Disease and the Risk of Fracture","volume":"125","author":"Van Staa","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.endonu.2012.01.002_bib1185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.2003.026799","article-title":"Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study","volume":"53","author":"Card","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.endonu.2012.01.002_bib1190","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1572-0241.2006.00571.x","article-title":"Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines\u2019 criteria","volume":"101","author":"Kornbluth","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1195","first-page":"1","article-title":"Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease","volume":"14","author":"Lewis","year":"2007","journal-title":"BSG Guidelines in Gastroenterology June"},{"key":"10.1016\/j.endonu.2012.01.002_bib1200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2036.2010.04554.x","article-title":"Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis","volume":"33","author":"Goodhand","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib1205","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","article-title":"Task Force of the FRAX Initiative. Interpretation and use of frax in clinical practice","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.endonu.2012.01.002_bib1210","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/00042737-200312000-00003","article-title":"Bone density improves with disease remission in patients with inflammatory bowel disease","volume":"15","author":"Reffitt","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/gast.2003.50106","article-title":"AGA technical review on osteoporosis in gastrointestinal diseases","volume":"124","author":"Bernstein","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.endonu.2012.01.002_bib1220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2004.02152.x","article-title":"Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease","volume":"20","author":"Franchimont","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib1225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.mcg.0000190762.80615.d4","article-title":"Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease","volume":"40","author":"Abreu","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1230","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2004.02097.x","article-title":"Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study","volume":"20","author":"Ryan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib1235","first-page":"181","article-title":"Impacto de la nutrici\u00f3n en la evoluci\u00f3n de la enfermedad inflamatoria intestinal","volume":"25","author":"Ballesteros-Pomar","year":"2010","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.endonu.2012.01.002_bib1240","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","article-title":"Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease","volume":"119","author":"Haderslev","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.endonu.2012.01.002_bib1245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1572-0241.2006.00372.x","article-title":"A double-blind placebo controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease","volume":"101","author":"Henderson","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1250","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2169\/internalmedicine.48.2005","article-title":"Alendronate Improves Low Bone Mineral Density Induced by Steroid Therapy in Crohn's Disease","volume":"48","author":"Tsujikawa","year":"2009","journal-title":"Inter Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1255","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2036.2003.01794.x","article-title":"A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease","volume":"18","author":"Bartram","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.endonu.2012.01.002_bib1260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/0003-4819-153-2-201007200-00262","article-title":"Screening for Osteoporosis: An Update for the U.S Preventive Services Task Force","volume":"153","author":"Nelson","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1265","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.84.12.4489","article-title":"The effects of anorexia nervosa on bone metabolism in female adolescents","volume":"84","author":"Soyka","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib1270","doi-asserted-by":"crossref","first-page":"790","DOI":"10.7326\/0003-4819-133-10-200011210-00011","article-title":"Prevalence and predictive factors regional for osteopenia in women with anorexia nervosa","volume":"133","author":"Grinspoon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.endonu.2012.01.002_bib1275","first-page":"33","article-title":"The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass","volume":"265","author":"Nancy","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2012.01.002_bib1280","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0025-6196(11)63994-3","article-title":"Long-term fracture risk among women with anorexia nervosa: A population-based cohort study","volume":"74","author":"Lucas","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.endonu.2012.01.002_bib1285","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jbmr.5650080511","article-title":"Outcome of bone mineral density in anorexia nervosa patients 11,7 years after first admission","volume":"8","author":"Herzog","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib1290","first-page":"63","volume":"7","author":"Jacobson-Dickman","year":"2010","journal-title":"Skeletal Abnormalities in Anorexia Nervosa IBMS BoneKEy"},{"key":"10.1016\/j.endonu.2012.01.002_bib1295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/10640266.2011.551636","article-title":"Osteoporosis in anorexia nervosa","volume":"19","author":"Mehler","year":"2011","journal-title":"Eat Disord"},{"key":"10.1016\/j.endonu.2012.01.002_bib1300","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF03347094","article-title":"Bone metabolism in adolescents with anorexia nervosa","volume":"34","author":"Misra","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endonu.2012.01.002_bib1305","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MED.0b013e32834b4bdc","article-title":"Bone health in anorexia nervosa","volume":"18","author":"Misra","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.endonu.2012.01.002_bib1310","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1542\/peds.86.3.440","article-title":"Decreased bone density in adolescent girls with anorexia nervosa","volume":"86","author":"Bachrach","year":"1990","journal-title":"Pediatrics"},{"key":"10.1016\/j.endonu.2012.01.002_bib1315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/eat.1081","article-title":"Predictors of low bone density in young adolescent females with anorexia nervosa and other dieting disorders","volume":"30","author":"Turner","year":"2001","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.endonu.2012.01.002_bib1320","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.medcli.2009.04.046","article-title":"Bone metabolism and fracture risk in anorexia nervosa","volume":"135","author":"Fern\u00e1ndez Soto","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.endonu.2012.01.002_bib1325","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1210\/jc.80.3.898","article-title":"The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa","volume":"80","author":"Klibanski","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib1330","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1210\/jc.85.9.3177","article-title":"Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women received from anorexia nervosa","volume":"85","author":"Karlsson","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib1335","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2004-1659","article-title":"Alendronate for the treatment of osteopenia in anorexia nervosa: A randomized, double-blind, placebo-controlled trial","volume":"90","author":"Golden","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib1340","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2003-031885","article-title":"Effects of risedronate on bone density in anorexia nervosa","volume":"89","author":"Miller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2012.01.002_bib1345","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0148607190014002139","article-title":"Progressive bone loss during long-term home parenteral nutrition","volume":"14","author":"Foldes","year":"1990","journal-title":"JPEN"},{"key":"10.1016\/j.endonu.2012.01.002_bib1350","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/0148607196020002105","article-title":"Bone loss and oral state in patients on home parenteral nutrition","volume":"20","author":"Von Wowern","year":"1996","journal-title":"JPEN"},{"key":"10.1016\/j.endonu.2012.01.002_bib1355","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1054\/clnu.2000.0380","article-title":"Clinical, social, and rehabilitation status of long-term home parenteral nutrition patients: results of a European multicentre survey","volume":"20","author":"Van Gossum","year":"2001","journal-title":"Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1360","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1359\/jbmr.2003.18.11.1989","article-title":"Osteoporosis on long-term home parenteral nutrition: a longitudinal study","volume":"18","author":"Cohen Solal","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.endonu.2012.01.002_bib1365","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1054\/clnu.2002.0548","article-title":"Prevalence of bone disease in patients on home parenteral nutrition","volume":"21","author":"Pironi","year":"2002","journal-title":"Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1370","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0148607104028005289","article-title":"Assessment of the longitudinal changes in patients receving home parenteral nutrition","volume":"28","author":"Haderslev","year":"2004","journal-title":"JPEN"},{"key":"10.1016\/j.endonu.2012.01.002_bib1375","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1155\/2007\/217897","article-title":"Canadian home parenteral nutrition registry: preliminary data on patient population","volume":"21","author":"Raman","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.endonu.2012.01.002_bib1380","first-page":"920","article-title":"Estudio transversal sobre la prevalencia de enfermedad metab\u00f3lica \u00f3sea y nutrici\u00f3n parenteral domiciliaria en Espa\u00f1a","volume":"25","author":"Mart\u00ednez","year":"2010","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.endonu.2012.01.002_bib1385","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/00365519609090580","article-title":"Body composition in patients on home parenteral nutrition","volume":"56","author":"Tjellesen","year":"1996","journal-title":"Scan J Clin Lab Invest"},{"key":"10.1016\/j.endonu.2012.01.002_bib1390","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.clnu.2004.04.003","article-title":"Bone mineral density in patients on home parenteral nutrition: a follow-up study","volume":"23","author":"Pironi","year":"2004","journal-title":"Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1395","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0148607102026006366","article-title":"Body composition changes in patients receiving home parenteral nutrition","volume":"26","author":"Matarese","year":"2002","journal-title":"JPEN"},{"key":"10.1016\/j.endonu.2012.01.002_bib1400","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0261-5614(96)80234-2","article-title":"Bone turnover in patients on home parenteral nutrition: a longitudinal observation by biochemical markers","volume":"15","author":"Pironi","year":"1996","journal-title":"Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1405","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ajcn\/76.2.482","article-title":"Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition","volume":"76","author":"Haderslev","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.endonu.2012.01.002_bib1410","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0148607106030006492","article-title":"Metabolic bone disease on patients receiving home parenteral nutrition: a Canadian study and review","volume":"30","author":"Raman","year":"2006","journal-title":"JPEN"}],"container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092212000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092212000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T07:38:02Z","timestamp":1640677082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1575092212000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":282,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1575092212000125"],"URL":"https:\/\/doi.org\/10.1016\/j.endonu.2012.01.002","relation":{},"ISSN":["1575-0922"],"issn-type":[{"value":"1575-0922","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}